NewAmsterdam Pharma loss widens to -$64.1M as revenue falls 80.7%; EMA positive opinion and PREVAIL interim analysis ahead

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~2 min read

Key Changes

• high

  Net loss widened to $64.1M from $17.4M, while operating loss widened 82% to $64.9M; the net loss increase was driven by non-operating factors, including a $4.6M warrant valuation loss and lower foreign exchange gains.

  MD&A: Operating Loss verify on EDGAR →
• high

  Revenue fell 80.7% to $3.7M from $19.1M, as the prior-year period included a $16.1M development cost contribution from Menarini that did not recur.

  MD&A: Revenue verify on EDGAR →
• high

  EMA's CHMP adopted a positive opinion for obicetrapib monotherapy and the ezetimibe fixed-dose combination; Menarini could launch in Germany and the UK in Q4 2026.

  MD&A: EMA regulatory progress verify on EDGAR →